Tirzepatide
A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity
Eli Lilly · Phase 2 · Completed · Enrollment 392
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Tirzepatide (TZP) + Mibavademab (MIBA) [Group A] | Obesity or overweight | n/r | 24 | n/r | n/r |
| TZP + Mibavademab-placebo (MIBA-PBO) [Group B] | Obesity or overweight | n/r | 24 | n/r | n/r |
| TZP + MIBA then Tirzepatide-placebo (TZP-PBO) + MIBA [Group C] | Obesity or overweight | n/r | 24 | n/r | n/r |
| TZP + MIBA [Group D] | Obesity or overweight | n/r | 24 | n/r | n/r |
| TZP + MIBA-PBO [Group E] | Obesity or overweight | n/r | 24 | n/r | n/r |
| TZP + MIBA-PBO then TZP-PBO + MIBA [Group F] | Obesity or overweight | n/r | 24 | n/r | n/r |
| TZP + MIBA-PBO then TZP + MIBA [Group G] | Obesity or overweight | n/r | 24 | n/r | n/r |
| TZP + MIBA-PBO then TZP-PBO + MIBA-PBO [Group H] | Obesity or overweight | n/r | 24 | n/r | n/r |